Immutep's (ASX:IMM) trial shows positive results for new head and neck cancer treatment

Immutep unveiled Phase 2b TACTI-003 trial results for eftilagimod alpha combined with KEYTRUDA in treating first-line metastatic head and neck squamous cell carcinoma patients with negative PD-L1 expression.

The combination demonstrated a 26.9% overall response rate in 26 assessable patients, indicating treatment advancement for this challenging subgroup.

The study suggests that efti with KEYTRUDA could broaden treatment-responsive patient populations sans chemotherapy.

Further trial data, including complete response rates, is eagerly awaited in early 2024.